<DOC>
	<DOCNO>NCT00555828</DOCNO>
	<brief_summary>Primary Objective The primary objective study evaluate safety feasibility transendocardial injection use Cordis Biosense NogaStarTM Mapping Catheter Biosense MyostarTM Left Ventricular Injection Catheter 25 M , 75 M , 150 M allogeneic mesenchymal precursor cell ( MPCs ) subject AMI . SecondaryObjective The secondary objective explore functional efficacy subsequent study design , well late-term dose related tolerance , : - Evaluating effect allogeneic MPCs exploratory efficacy endpoint related cardiac function Days 90 , 180 , 1 year - Evaluating change baseline Medical Outcome Study Short Form ( SF-36 ) , Kansas City Cardiomyopathy Questionnaire , Seattle Angina Questionnaire , New York Heart Association Classification 30 day , 3 6 month , 1 , 2 , 3 year - Evaluating follow-up safety Day 360 - Providing preliminary data support dose selection future study</brief_summary>
	<brief_title>Safety Study Allogeneic Mesenchymal Precursor Cells ( MPCs ) Subjects With Recent Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>1 . Age 18 year old . 2 . An STelevation MI ( STEMI ) within 2 10 day study enrollment . The STEMI must document ECG STsegment elevation &gt; 1 mm least 2 contiguous precordial lead least 2 adjacent limb lead . If history previous AMI prior qualify MI , must document EF ≥ 50 % 2D echocardiogram within 12 month enrollment . 3 . Successful percutaneous revascularization Thrombolysis Myocardial Infarction ( TIMI ) 3 flow infarctrelated artery . 4 . A baseline 2D echocardiogram EF ≥ 30 ≤ 50 % follow PCI . 5 . Creatinine level ≤ 1.5mg/dL within 24 hour study procedure . 6 . Hematocrit ≥ 30 % within 24 hour study procedure . 7 . White Blood Cell count &lt; 20k/mm3 within 24 hour study procedure . 8 . Platelet count ≥ 100k/mm3 within 24 hour study procedure . 9 . INR ≤ 1.7 within 24 hour study procedure . 10 . Total bilirubin &lt; 3 mg/dL , albumin &gt; 2.8 g/dL , aspartate aminotransferase ( AST ) ≤ 2.5x upper limit normal , gamma glutamyltranspeptidase ( GGT ) ≤ 1.5 x upper limit normal . 11 . If subject partner childbearing potential , must willing use adequate contraception ( hormonal barrier method abstinence ) time screen period least 16 week surgery . 12 . Female subject childbearing potential must negative serum pregnancy test screening ( within 2 week enrollment ) negative serum urine pregnancy test day cell implantation . 13 . Willing able understand , sign , date Informed Consent Form ( ICF ) . 14 . Must willing return require followup visit . 15 . Must able follow postoperative management program . 1 . Subject hemodynamically unstable Day 5 postAMI demonstrate follow : 1 . Killip Class 4 indicative cardiogenic shock . 2 . Requirement intraaortic balloon pump IV inotropic support maintenance mean arterial blood pressure ≥ 60 mmHg . 2 . Sustained ventricular tachycardia demonstrate QRS complex wider 120 msec , last &gt; 30 sec , &gt; 100 bpm occur &gt; 48 hour follow PCI without identifiable , reversible cause ( ie , electrolyte imbalance ) . 3 . Further revascularization plan next 30 day . 4 . Chronic atrial fibrillation . 5 . A wall thickness target region &lt; 8 mm determine 2D echocardiography ( target region defined time NOGA® mapping ) . 6 . An LV thrombus . 7 . Severe peripheral vascular disease preclude femoral artery access determine time original catheterization . 8 . Aortic stenosis determine valve area le 1 cm2 prohibits catheter access LV . 9 . Echocardiographic evidence hypertrophic cardiomyopathy indicate heart muscle thickness &gt; 15 mm . 10 . Human immunodeficiency virus ( HIV ) 11 . Serum glucose level ≥ 400 mg/dl within 24 hour study procedure 12 . Serum glucose level 300400 mg/dl presence urine ketone within 24 hour study procedure . 13 . Claustrophobic , medical condition contradiction impede perform baseline MRI study . 14 . An active uncontrolled infection . 15 . A prosthetic aortic valve . 16 . Presence ≥ 20 % antiHLA antibody titer and/or antibody specificity donor HLA antigen . 17 . A current prior history within last 3 year neoplasm ( exclude basal cell ) and/or active neoplasm within last 24 month . 18 . A known hypersensitivity dimethyl sulfoxide ( DMSO ) , murine and/or bovine product . 19 . Pregnancy breastfeed . 20 . Imprisoned time enrollment . 21 . A treatment and/or uncompleted followup treatment investigational therapy within 6 month implantation surgery intent participate investigational drug cell therapy study 3year followup period study . 22 . Active participation research therapy cardiovascular repair/regeneration . 23 . A prior recipient stem precursor cell therapy cardiac repair . 24 . Any medical condition would affect investigator 's ability evaluate subject 's condition could compromise subject 's safety . 25 . Any condition , judgment investigator , would prohibit subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Myocardial infarct</keyword>
	<keyword>Infarction</keyword>
</DOC>